The Milan trial NSABP B-6 and the EORTC10801 trial both showed that breast-conserving surgery can achieve the same survival rate as radical surgery as long as the indications are strictly controlled and the treatment plan is standardized, which can greatly improve the quality of life of breast cancer patients. The main indications for breast-conserving surgery are: Single clinical and mammographic lesion Tumor diameter Q3cm, more than 2cm from the nipple No symptoms of local progression Lymph nodes N0-1 Good nuclear differentiation and histological grading Patients aged 30-60 years old voluntarily request breast-conserving surgery and there are no absolute contraindications Localized more advanced cancer down to stage I or II No extensive cancer components next to the cancer foci No lymphatic vessels within the cancer foci No lymphatic thrombus